Skip to main content
Che Wei Chang on Muck Rack

Che Wei Chang

As seen in: ACS Publications, MDEdge
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Che Wei

Contact Che Wei, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

s-Block Metal Catalysts for the Hydroboration of Unsaturated Bonds

|
By Marc Magre, Magnus Rueping, Che Wei Chang
| ACS Publications
1. Introduction Hydroboration─the addition of a boron–hydrogen bond to an unsaturated bond─is a useful and atom-economic transformation for the synthesis of organoboranes. The addition of boranes (HBR2) to C═O or C═N bonds (Scheme 1) results in formation of a boron–oxygen or nitrogen bond, which, along with hydrolysis, constitutes a two-step process equivalent to reduction.
Open in Who Shared Issue with article?

Deep learning approach based on superpixel segmentation assisted labeling for automatic pressure ulcer diagnosis

|
By New Taipei, Yuan Ze, Che Wei Chang, Mesakh Christian
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Che Wei Chang , Mesakh Christian, Dun Hao Chang, Feipei Lai, Tom J. Liu, Yo Shen Chen, Wei Jen Chen Che Wei Chang, Mesakh Christian, Dun Hao Chang, Feipei Lai, Tom J. Liu, Yo Shen Chen, Wei Jen Chen Published: February 17, 2022 https://doi.org/10.1371/journal.pone.0264139 Figures Abstract A pressure ulcer is an injury of the skin and underlying tissues adjacent to a bony eminence.
Open in Who Shared Issue with article?

Prostate-Specific Antigen Decline >50% After 4 Weeks of Treatment Is an Indicator of Better Progression Free and Overall Survival Both With Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer | MDedge

|
By Mir Ali, Sanjay Hinduja, William Sun, Che Wei Chang
| MDEdge Verified
BACKGROUND: Abiraterone (ABI) and Enzalutamide (ENZA) are the most common medications used for metastatic castrate resistant prostate cancer (mCRPC). Post treatment prostate specific antigen (PSA) changes correlate with prognosis (1). Early PSA decline defined as PSA decline by >50 % at 4 weeks after starting treatment compared to baseline has been demonstrated to corresponds with improved PSA progression-free survival (PSA PFS) and overall survival (OS) (2).
Open in Who Shared Issue with article?
See all 3 articles